Faculty Collaboration Database

Recently disclosed chemical entities as potential candidates for management of tuberculosis. Pharm Pat Anal 2015;4(4):317-47

Date

07/16/2015

Pubmed ID

26174569

DOI

10.4155/ppa.15.13

Scopus ID

2-s2.0-85050578152 (requires institutional sign-in at Scopus site)   3 Citations

Abstract

Tuberculosis (TB) is one of the deadliest infectious diseases worldwide. The drug discovery process of novel, safe and effective agents to combat TB involves identification of new molecular targets and novel chemical scaffolds. The current anti-TB drug pipeline includes several small molecules with more to follow as new candidates are disclosed. This review highlights the most significant findings described in 78 international, European and US patents for chemically diverse compounds as prospective anti-TB medications. Main points of emphasis include chemical classification, in vitro and in vivo activity, ADME/Tox profile and mycobacterial target as described in each patent. The collective mass of compounds disclosed in the reviewed patents introduces new candidates as potential therapeutic agents for TB infections.

Author List

Stec J, Abourashed EA

Author

Ehab A. Abourashed PhD Professor in the School of Pharmacy Administration department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Animals
Antitubercular Agents
Disease Management
Drug Discovery
Humans
Tuberculosis